Venrock Healthcare Capital Partners II, L.P. 13D and 13G filings for Cogent Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 5:47 pm Purchase | 2024-09-30 | 13G | Cogent Biosciences, Inc. COGT | Venrock Healthcare Capital Partners II, L.P. | 11,516,667 9.990% | 2,477,823 (+27.41%) | Filing |
| 2024-02-14 8:33 pm Purchase | 2023-12-31 | 13G | Cogent Biosciences, Inc. COGT | Venrock Healthcare Capital Partners II, L.P. | 9,038,844 9.990% | 1,729,716 (+23.67%) | Filing |
| 2023-02-14 4:55 pm Purchase | 2022-12-31 | 13G | Cogent Biosciences, Inc. COGT | Venrock Healthcare Capital Partners II, L.P. | 7,309,128 9.990% | 3,007,002 (+69.90%) | Filing |
| 2022-02-14 4:14 pm Purchase | 2021-12-31 | 13G | Cogent Biosciences, Inc. COGT | Venrock Healthcare Capital Partners II, L.P. | 4,302,126 9.990% | 4,302,126 (New Position) | Filing |